M&A Deal Summary

Biogen Acquires TYSABRI

On February 6, 2013, Biogen acquired life science company TYSABRI from Elan for 3.3B USD

Acquisition Highlights
  • This is Biogen’s 4th transaction in the Life Science sector.
  • This is Biogen’s 2nd largest (disclosed) transaction.
  • This is Biogen’s 3rd transaction in the United States.

M&A Deal Summary
Date 2013-02-06
Target TYSABRI
Sector Life Science
Buyer(s) Biogen
Sellers(s) Elan
Deal Type Divestiture
Deal Value 3.3B USD

Target

TYSABRI

United States
TYSABRI is a prescription medicine used to treat adults with relapsing forms of Multiple Sclerosis(MS). TYSABRI can slow the worsening of symptoms common in people with MS and can decrease the number of flare-ups (relapses).

Search 200,388 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Biogen

Cambridge, Massachusetts, United States
Category Company
Founded 1978
Sector Life Science
Employees7,570
Revenue 9.8B USD (2023)
DESCRIPTION
Entrance to Biogen office in Weston, Massachusetts.
Entrance to Biogen office in Weston, Massachusetts.

Biogen is a biopharmaceutical company focused on discovering, developing, and delivering worldwide therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Biogen was founded in 1978 and is based in Cambridge, Massachusetts.

DEAL STATS #
Overall 4 of 9
Sector (Life Science) 4 of 9
Type (Divestiture) 1 of 2
Country (United States) 3 of 6
Year (2013) 1 of 1
Size (of disclosed) 2 of 8
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2012-02-14 Stromedix

Cambridge, Massachusetts, United States

Stromedix, Inc., is a privately held biotechnology company based in Cambridge, Massachusetts, focused on innovative therapies for fibrosis and organ failure. Stromedix's investors include Atlas Venture, New Leaf Venture Partners, Bessemer Venture Partners, Red Abbey Venture Partners, and Frazier Healthcare.

Buy $562M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-01-11 Convergence Pharmaceuticals

Cambridge, United Kingdom

Convergence Pharmaceuticals is focused on the development of novel, high value analgesics for the treatment of chronic pain. Innovative approaches to the treatment of chronic pain are desperately needed, most notably because there are a high number of sufferers and current treatments are characterised by poor efficacy and side effects.

Buy $675M

Seller(S) 1

SELLER

Elan

Dublin, Ireland
Category Company
Founded 1969
Sector Healthcare Services
DESCRIPTION

Elan is a biotechnology company, headquartered in Dublin, Ireland, committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. It focused on discovering and developing advanced therapies in neurodegenerative and autoimmune diseases.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
Country (United States) 1 of 1
Year (2013) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2003-01-17 Pharma Marketing

Hamilton, Bermuda

Pharma Marketing was established to fund the marketing of drugs.

Buy -
Mergr

Product

Company

Legal